



Aleta Biotherapeutics Announces Oral Presentation at the 61st American Society of Hematology Annual Meeting (ASH)

Novel CD19-anti-CD20 bridging protein technology to prevent and reverse CD19-negative relapse from CAR19 T cell treatment in vivo to be presented on December 7

NATICK, Mass., December 2, 2019 – [Aleta Biotherapeutics](#), a privately held immuno-oncology company focused on transforming cellular therapeutics to allow a broad spectrum of cancer indications to be targeted, today announced that Paul Rennert, Ph.D., President and Chief Scientific Officer, will deliver an oral presentation at the 61st ASH Annual Meeting & Exposition, December 7 – 10, 2019, Orange County Convention Center, Orlando, FL.

“The 61st ASH Annual Meeting will be an important opportunity to present mechanistic studies and extensive *in vitro* and *in vivo* results from our novel CD19-anti-CD20 bridging protein technology,” said Paul Rennert, Ph.D., President and Chief Scientific Officer of Aleta Biotherapeutics. “We look forward to advancing the development of this novel therapy based on the data we will be presenting on December 7.”

Oral Presentation Details

Title: [252 A Novel CD19-Anti-CD20 Bridging Protein Prevents and Reverses CD19-Negative Relapse from CAR19 T Cell Treatment *in vivo*](#)

Session Name: 703. Adoptive Immunotherapy: Mechanisms and New Approaches: Mechanisms

Presenter: Paul Rennert, Ph.D.

Session Date: Saturday, December 7, 2019

Session Time: 2:00 PM - 3:30 PM

Presentation Time: 3:15 PM

Location: Orange County Convention Center, Valencia A (W415A)

About Aleta Biotherapeutics

Aleta Biotherapeutics is an immuno-oncology company focused on transforming cellular therapeutics to allow a broad spectrum of cancer indications to be targeted, including currently intractable solid tumors. The company was founded by Paul Rennert and Roy Lobb, who bring extensive scientific and leadership experience in immunology, oncology and drug development to this new enterprise. Aleta has created a unique portfolio of multi-antigen targeting solutions for cell therapy, designed to address the critical issues of CAR-T persistence, tumor antigen loss leading to patient relapse, and tumor antigen heterogeneity. For more information, visit www.aletabio.com.

Contact:

Rob Kloppenburg

MacDougall

(617) 930-5595

rkloppenburg@macbiocom.com